Effects of Losartan, Empagliflozin, and Their Combination on Uric Acid Concentrations in People With Type 2 Diabetes

Danii L.S. Suijk, Preciosa X.C. Simson, Rosalie A. Scholtes, Charlotte M. Mosterd, Anne C. Hesp, Ewout J. Hoorn, Petter Bjornstad, Daniel H. van Raalte · 2026

Read Effects of Losartan, Empagliflozin, and Their Combination on Uric Acid Concentrations in People With Type 2 Diabetes by Danii L.S. Suijk, Preciosa X.C. Simson, Rosalie A. Scholtes, Charlotte M. Mosterd, Anne C. Hesp, Ewout J. Hoorn, Petter Bjornstad, Daniel H. van Raalte (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13571260.txt.

Description

Danii L. S. Suijk and colleagues write, in a 2026 letter, about testing losartan, empagliflozin, and both together for lowering blood uric acid in people with type 2 diabetes. High uric acid tracks with heart and kidney disease in this group. Twenty-four participants aged from twenty-five upward entered the comparison of the two familiar drugs.

Each drug is thought to raise uric acid loss in urine through the same kidney transporter. One is a proven diabetes and kidney protector. The other is a blood pressure drug with a known uric acid benefit in a landmark trial. Because the pair is often prescribed together, the study separates their individual and combined effects on uric acid levels and urine clearance. The design answers a practical question for combination prescribing.

Catalog record

CREATORDanii L.S. Suijk, Preciosa X.C. Simson, Rosalie A. Scholtes, Charlotte M. Mosterd, Anne C. Hesp, Ewout J. Hoorn, Petter Bjornstad, Daniel H. van Raalte
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE8293
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13571260

Browse the full library · About the Tower of Babel